Skip links

Tag: asco2020

ASCO Webinar Summary: Gastric Cancer

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01) ( ) Author, Company: Kohei Shitara, MD Abstract Number: 4513 Indications: Advanced HER2+ gastric or gastroesophageal junctional adenocarcinoma Interventions: Enhertu (Trastuzumab deruxtecan) Background and

ASCO Webinar Summary: Pancreatic Cancer

Liposomal irinotecan plus fluorouracil/leucovorin versus folfirinox as the second-line chemotherapy for patients with metastatic pancreatic cancer (Link for full article)  Author, Company : Hongjae Chon, MD, Korean Cancer Study Group (KCSG) Abstract Number: 4624 Indications : Metastatic pancreatic cancer (mPC) Interventions : Liposomal irinotecan plus fluorouracil/leucovorin, folfirinox Background

ASCO Webinar Summary: Breast Cancer

KEYNOTE-355: A Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer ( Author, Company: Javier Cortes, MD, PhD Abstract Number: 1000 Indications: Triple Negative Breast Cancer Interventions: Pembrolizumab plus chemotherapy Background and objectives:

Call Now Button 
Contact Us